Match Document Document Title
8834891 Immunogenic compositions comprising Lawsonia intracellularis  
The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and...
8834888 Adjuvanting meningococcal factor H binding protein  
Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate...
8834897 Methods for using tetanus toxin for beneficial purposes in animals (mammals)  
Methods of using tetanus toxin to modulate or control neural functions or nonneural cellular activities at selected sites in animals, particularly in mammals, and more particularly in humans, are...
8834894 Compositions and methods for vaccinating against HSV-2  
This invention relates to therapeutic polynucleotide compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response...
8834898 Cholera toxin chimera and its use as a staph vaccine  
The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus. One embodiment of the present invention provides a method of...
RE45137 Adjuvanted meningococcus compositions  
A combination of CpG oligonucleotides and polymer microparticles is an extremely effective adjuvant for Neisserial antigens. The invention therefore provides a composition comprising: (a) a...
8834881 Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof  
Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses....
8835603 Agents for the treatment of celiac disease  
The invention provides agents and vaccines for treating and diagnosing celiac disease. In particular, the present invention provides a combination of three peptides that are useful for treating...
8834887 Drug for suppressing pathogen occurring in vivo  
To provide a drug for actively metabolizing or excreting a pathogen occurring in vivo. The present invention is directed to a compound which is formed of (A) an adsorbent for a pathogen occurring...
8828406 Influenza viruses and uses thereof  
Described herein are chimeric influenza virus gene segments and nucleic acid sequences encoding such chimeric influenza virus gene segments. A chimeric influenza virus gene segment described...
8828405 Method to enhance an immune response of nucleic acid vaccination  
A composition comprising liposomes associated with a nucleic acid operatively encoding an antigenic protein and with an assistor protein, wherein the assistor protein shares at least one epitope...
8828408 Compositions and methods for vaccinating against HSV-2  
This invention relates to therapeutic polynucleotide compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response...
8828957 Methods for generating immunity to antigen  
Provided are methods of generating an immune response to an antigen. The method comprises priming an individual by administering an expression vector encoding the antigen. The vectors comprises a...
8828404 Vaccine and method for treatment of neurodegenerative diseases  
Methods and compositions are provided for treatment of neurodegenerative diseases in which there is accumulation of misfolded and/or aggregated proteins, excluding prion diseases. In particular,...
8828402 Augmentation of titer for vaccination in animals  
The disclosure relates to a composition added to animal feed used in combination with a vaccine to enhance the effectiveness of the vaccine. Amongst other effects, the composition raises the titer...
8821882 Vaccine preparation for neospora caninum infection  
A vaccine preparation characterized in that Neospora caninum-derived dense granule protein 7 or apical membrane antigen 1 or an immunologically active variant or derivative thereof is included in...
8821883 Method of treating B cell cancers by administering truncated BAFF receptors  
The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered O-linked glycosylation pattern. The disclosure also...
8821891 Live attenuated rotavirus vaccine for oral administration  
The invention provides liquid rotavirus formulations that are suitable for oral administration to human infants. In particular the invention provides pharmaceutical compositions and vaccines,...
8821881 Quil A fraction with low toxicity and use thereof  
Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance...
8822418 Treatment of muscular dystrophies and related disorders  
The invention provides, among other aspects, compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan;...
8822182 Chimeric antigen-specific T cell-activating polypeptides  
The invention provides an immunogenic or antigenic polypeptide containing a translocation domain, a peptide epitope, at least one biologically active agent, and cleavage sites. These polypeptides...
8821851 Inflammation-inhibitory serum factors and uses thereof  
Disclosed are methods of purifying compounds that reduce or prevent an inflammatory response in a mammal, use of such compounds in treating a mammal having or being at risk of developing...
8821884 Compositions and methods using MD-2 mutants and chimeric proteins  
The invention provides compositions and methods for the targeted bacteriostatic and antibacterial agents and for treatment of sepsis caused by infectious diseases, such as bacterial and fungal...
8821897 Viral adjuvants  
The present invention provides viral adjuvants for enhancing an immune response to an immunogen. In particular embodiments, the viral adjuvant is an alphavirus adjuvant or a Venezuelan Equine...
8821885 Immunogenic compositions and methods  
The invention is directed to immunogenic compositions, and methods for their use in the formulation and administration of therapeutic and prophylactic pharmaceutical agents. In particular, the...
8815277 In situ forming hydrogel and biomedical use thereof  
Disclosed are in situ-forming injectable hydrogel and medical uses thereof. In the in situ-forming injectable hydrogel two or more homogeneous or heterogeneous polymers are bonded to each other by...
8815248 Modulation of immunity and CEACAM1 activity  
The present technology comprises methods for regulating an the immune system, and in particular methods for the regulation of a specific immune response, including the regulation of lymphocyte...
8815255 Use of Mycoplasma bovis antigen  
The present invention relates to combination vaccines and/or the combined use of immunogenic compositions for the treatment and/or prophylaxis of cattle against microbiological infections, wherein...
8815229 Granulysin in immunotherapy  
Methods of stimulating or enhancing an immune response in a host are disclosed. The methods include contacting a monocyte with 15 kD granulysin thereby producing a monocyte-derived dendritic cell....
8815256 Induction of tumor immunity by variants of folate binding protein  
The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The...
8815253 Compositions for inducing immune responses  
The invention provides, inter alia, immunogenic compositions that comprise (a) a first antigen, (b) at least first and second adjuvants, wherein the first adjuvant comprises microparticles and...
8808707 Pneumococcal dosing regimen  
Methods of immunizing older adult subjects against Streptococcus pneumoniae infection are provided. Provided methods comprise immunization of naïve adult subjects with a conjugated pneumococcal...
8809047 Herpes simplex virus vaccines  
The present invention is directed to Herpes simplex-2 viruses that may be used in vaccines to immunize patients against genital herpes.
8808664 Lipidated glycoprotein particles and methods of use  
Lipidated micro- or macroparticles are prepared by covalently linking a glycoprotein, typically collagen, with at least one lipid. An amino group in the glycoprotein is joined with a primary amine...
8808703 Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc  
The invention provides a novel class of compounds viz. generally lipopeptides like Pam3CSK4, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using...
8808692 Compositions comprising immunoreactive reagents and saponins, and methods of use thereof  
The present invention relates to pharmaceutical compositions that are useful for the prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer),...
8808710 Method of preparing an immunologically-active adjuvant-bound dried vaccine composition  
The disclosure provides a method of preparing an immunologically-active adjuvant-bound freeze dried vaccine composition. A specific embodiment provides a stable vaccine composition comprising an...
8808708 Multivalent pneumococcal polysaccharide-protein conjugate composition  
An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared...
8802098 Methods of promoting antitumor immunity by administering CD40 agonists and alpha-galactosyl ceramide  
Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (α-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune...
8802112 Treatment and prevention of Gardnerella vaginalis infections  
The present invention is drawn to the nucleic and amino acid sequences encoding vaginolysin (VLY) toxin from Gardnerella vaginalis, and biologically active fragments and variants thereof. The...
8802110 Influenza treatment and/or characterization, human-adapted HA polypeptides; vaccines  
The present invention provides, among other things, methods, reagents, and systems for the treatment, detection, analysis, and/or characterization of influenza infections.
8802104 Parathyroid hormone receptor activation and stem and progenitor cell expansion  
The invention relates to methods for manipulating hematopoietic stem or progenitor cells, mesenchymal stem cells, epithelial stem cells, neural stem cells and related products through activation...
8802105 Antibacterial compositions  
The present invention relates to oral antibacterial compositions comprising trihydroxybenzoate derivatives, e.g., useful for the treatment of gum diseases (e.g., gingivitis or periodontitis) and...
8802158 Methods of use of probiotic Lactobacilli for companion animals  
According to the present invention there are provided methods of use in companion animals of probiotic bacteria of the genus Lactobacilli.
8796227 Peptides for inhibiting chemokine binding to chemokine receptors  
Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed...
8795676 Genes encoding major capsid protein L1 of human papilloma virus  
The present invention discloses a codon-optimized gene encoding major capsid protein L1 of human papilloma virus, which is capable, after transduced into a yeast cell, of efficiently expressing...
8795634 Absorption of therapeutic agents across mucosal membranes or the skin  
Absorption of a therapeutic agent across a mucosal membrane or the skin can be enhanced using an absorption enhancer comprising a hydroxy fatty acid ester of polyethylene glycol.
8790655 Conjugates of synthetic TLR agonists and uses therefor  
The invention provides TLR agonists and conjugates thereof useful in vaccines and to prevent, inhibit or treat a variety of disorders including pathogen infection and asthma.
8790661 Exosomes derived from reticulocytes infected with Plasmodium sp., method for obtaining them and uses thereof  
The present invention belongs to the field of vaccines for the prevention and prophylaxis against malaria, more specifically it relates to exosomes isolated from reticulocytes infected with...
8790635 Live, oral vaccine for protection against Shigella dysenteriae serotype 1  
The invention relates to Salmonella typhi Ty21a comprising core-linked Shigella dysenteriae serotype 1 O-specific polysaccharide (O-Ps) and DNA encoding O antigen biosynthesis, said DNA selected...